Cross-vaccination Study of GSK Biologicals' Lyophilized Formulation of the Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs GSK 1437173A (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Registrational
- Acronyms Zoster-056
- Sponsors GlaxoSmithKline
- 06 Jul 2017 Planned primary completion date changed from 1 Nov 2017 to 2 Jan 2019.
- 12 Jan 2017 Planned End Date changed from 1 Aug 2018 to 1 Jan 2019.
- 12 Jan 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2017.